Novavax’s NanoFlu Fast Track’d in U.S.; shares up

Novavax (NASDAQ:NVAX) was up 18% premarket on average volume following its announcement that the FDA has granted Fast Track status for its planned marketing application for recombinant quadrivalent flu vaccine NanoFlu.

Topline data from a Phase 3 study should be available by quarter-end.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

https://seekingalpha.com/news/3531988-novavaxs-nanoflu-fast-trackd-in-u-s-shares-up-18-premarket